In a new study, researchers have for the first time demonstrated that baboon embryonic stem cells can be programmed to completely restore a severely damaged artery.
These early results show promise for eventually developing stem cell therapies to restore human tissues or organs damaged by age or disease.
“We first cultured the stem cells in petri dishes under special conditions to make them differentiate into cells that are the precursors of blood vessels, and we saw that we could get them to form tubular and branching structures, similar to blood vessels,” John L. VandeBerg, chief scientific officer from Texas Biomedical Research
Many of us know by now that stem cells are remarkably fluid in the types of cells they can become. But this fluidity, or pluripotency, comes with a price. Several studies have shown that the body’s immune system will attack and reject even genetically identical transplanted stem cells, making it difficult to envision their usefulness for long-term therapies.
Now Stanford cardiologist Joseph Wu, MD, PhD, and his colleagues have shown that coaxing the stem cells to become more-specialized (a process known as differentiation) before transplantation allows the body to recognize and tolerate the cells. Their research was published today in
The past few years brought high development in obtaining and culturing autologous adult stem cells. In this paper we review publications of experimental investigations and clinical trials of the muscle-derived cells and the application in the treatment of stress urinary incontinence among women. Mesenchymal stem cells (MSCs) can be obtained from bone marrow but it is associated with a painful biopsy procedure.
Collection of muscle-derived stem cells (MDSCs) is less harmful because the skeletal muscle biopsy is performed with a small caliber needle in local anesthesia. The stem-based therapy could be the next
In 2010, L V Prasad Eye Institute (LVPEI) moved away from culturing corneal stem cells in a petri-dish in the laboratory to directly culturing and expanding them on the patient’s eye.
This ingenuous technique was termed Simple Limbal Epithelial Transplantation (SLET) to contrast it from the radical tissue transplants and complex culture techniques that were the standard of care at that time.
SLET completely eliminates the need for laboratory based processing thereby making it possible to be executed by any well trained surgeon anywhere (…)
A pilot clinical trial was done on a small sample size including 125 patients, 65 adults and 60
International Stem Cell Corporation announced that scientists in its wholly-owned subsidiary, Lifeline Cell Technology (LCT), have developed a technology to modify human stem cells by using engineered proteins, called “transducible transcription factors” or “TTFs.” TTFs are designed to pass into stem cells and direct the stem cells to change into specific cell types that can be both therapeutically-useful and can be used as revenue-generating research products.
In contrast to more traditional cell therapy methods this technology does not require the use of viruses or chemicals, and has the potential to produce safe therapeutic cells from stem cells. In addition, the